Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
SNYR 
Synergy CHC Corp. Common Stock (SNYR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: SNYR (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $10
1 Year Target Price $10
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 33.96% | Avg. Invested days 39 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  5.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 32.00M USD | Price to earnings Ratio 11.83 | 1Y Target Price 10 |
Price to earnings Ratio 11.83 | 1Y Target Price 10 | ||
Volume (30-day avg) 1 | Beta 1.09 | 52 Weeks Range 1.19 - 10.00 | Updated Date 08/15/2025 |
52 Weeks Range 1.19 - 10.00 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.3 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 7.21% | Operating Margin (TTM) 23.84% |
Management Effectiveness
Return on Assets (TTM) 26.73% | Return on Equity (TTM) -361.12% |
Valuation
Trailing PE 11.83 | Forward PE 7.4 | Enterprise Value 59941426 | Price to Sales(TTM) 0.95 |
Enterprise Value 59941426 | Price to Sales(TTM) 0.95 | ||
Enterprise Value to Revenue 1.78 | Enterprise Value to EBITDA 9.07 | Shares Outstanding 9014110 | Shares Floating 2626531 |
Shares Outstanding 9014110 | Shares Floating 2626531 | ||
Percent Insiders 70.47 | Percent Institutions 7.11 |
Upturn AI SWOT
Synergy CHC Corp. Common Stock
Company Overview
History and Background
Synergy CHC Corp. was a consumer health company focused on acquiring and developing over-the-counter (OTC) healthcare brands. It no longer exists as a public company. It was founded to acquire, market, and distribute consumer healthcare brands.
Core Business Areas
- Consumer Healthcare Products: Synergy CHC Corp. focused on acquiring and managing a portfolio of established consumer healthcare brands across various OTC categories, like cough/cold, skincare, and vitamins.
Leadership and Structure
Information about the leadership and structure of Synergy CHC Corp. as a historical entity is difficult to ascertain beyond general corporate structure for OTC companies.
Top Products and Market Share
Key Offerings
- BC Powder: BC Powder is a pain reliever. Market share data is not currently available. Competitors include brands like Bayer, Excedrin, and Goody's.
- Alka-Seltzer Plus: Alka-Seltzer Plus is a cold and flu medication. Market share data is unavailable. Competitors include NyQuil, DayQuil, and Theraflu.
Market Dynamics
Industry Overview
The OTC market is driven by consumer demand for self-treatment options. It is characterized by established brands and a focus on brand recognition and distribution.
Positioning
Synergy CHC aimed to compete by acquiring established brands and leveraging distribution channels. Its success depended on brand management and efficient marketing.
Total Addressable Market (TAM)
The global OTC market is valued in the hundreds of billions of dollars. Synergy CHC aimed to capture a portion of this TAM through its portfolio of brands.
Upturn SWOT Analysis
Strengths
- Established brands in portfolio
- Distribution network
- Brand recognition of certain products
Weaknesses
- Reliance on acquired brands, lacking organic growth
- Competition from larger players with greater resources
- Dependence on distribution network relationships
Opportunities
- Further acquisitions of complementary brands
- Expansion into new markets
- Innovation in product formulations
Threats
- Intense competition in the OTC market
- Changing consumer preferences
- Regulatory changes
Competitors and Market Share
Key Competitors
- Bayer (BAYRY)
- Procter & Gamble (PG)
- Johnson & Johnson (JNJ)
Competitive Landscape
Synergy CHC competed with larger, more established players. Its success relied on brand management and efficient operations.
Growth Trajectory and Initiatives
Historical Growth: Historical growth trends unavailable.
Future Projections: Future projections unavailable.
Recent Initiatives: Focused on acquiring and growing existing consumer healthcare brands.
Summary
Synergy CHC was an OTC consumer healthcare company that focused on acquiring and managing brands. Its strength lay in the recognition of its existing product lines, but it faced intense competition from much larger companies. To grow, Synergy CHC needed to innovate or continue to acquire other smaller product lines. The company no longer exists as a public entity.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Publicly available information
- Company press releases (historical)
- Market research reports
Disclaimers:
This analysis is based on limited publicly available information. Market share data is approximate. This is not financial advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Synergy CHC Corp. Common Stock
Exchange NASDAQ | Headquaters Westbrook, ME, United States | ||
IPO Launch date 2016-01-04 | CEO & Chairman Mr. Jack Ross | ||
Sector Healthcare | Industry Medical Distribution | Full time employees 21 | Website https://synergychc.com |
Full time employees 21 | Website https://synergychc.com | ||
Synergy CHC Corp. provides consumer health care, beauty, and lifestyle products in the United States, Canada, and the United Kingdom. It offers brain health nutritional supplements under the FOCUSfactor brand name; and lifestyle and wellness products and accessories, including tea, shakes, lollipops, supplements, apparel, and exercise accessories under the Flat Tummy brand name. The company also provides hand care products under the Hand MD brand name; beauty products for the eyes, lips, brows, cheeks, and skin under the Perfekt Beauty brand; shapewear, bralettes, and panties under Sneaky Vaunt brand; eyelash enhancement products under The Queen Pegasus brand; topical treatments for neuropathic pain under Neuragen brand; and over-the-counter medications under UrgentRx brand. It sells its products through club, mass drug, and other retailers. The company was formerly known as Synergy Strips Corp. and changed its name to Synergy CHC Corp. in August 2015. The company was incorporated in 2010 and is based in Westbrook, Maine.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.